Orbsen Therapeutics announces encouraging interim results from the NEPHSTROM proof of concept clinical study evaluating ORBCEL™ cell therapy in patients with diabetes and advanced chronic kidney disease

2023-01-31T23:16:28+00:00January 31st, 2023|

GALWAY, Ireland, Jan. 26, 2023 /PRNewswire/ -- Orbsen Therapeutics Limited ("Orbsen"), a global leader in stromal cell immunotherapies, today announces encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for Diabetic Kidney Disease (NEPHSTROM). NEPHSTROM is a randomized, double-blind, placebo-controlled Phase 1/2a, trial evaluating the safety, tolerability and preliminary efficacy of an off-the-shelf allogeneic bone [...]